EPGNF Stock - Epigenomics AG
Unlock GoAI Insights for EPGNF
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $339,227 | $485,000 | $6.20M | $842,000 |
| Gross Profit | $-12,422 | $282,315 | $365,000 | $6.07M | $697,000 |
| Gross Margin | N/A | 83.2% | 75.3% | 97.8% | 82.8% |
| Operating Income | $-1,178,080 | $-4,176,539 | $-12,051,000 | $-2,354,000 | $-11,627,000 |
| Net Income | $-3,470,057 | $-4,463,523 | $-12,024,000 | $-2,428,000 | $-11,686,000 |
| Net Margin | N/A | -1315.8% | -2479.2% | -39.1% | -1387.9% |
| EPS | $-3.96 | $-5.23 | $-14.78 | $-4.33 | $-39.67 |
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
Visit WebsiteEarnings History & Surprises
EPGNFEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Apr 29, 2025 | — | — | — | — |
Q1 2025 | Jan 21, 2025 | — | — | — | — |
Q3 2024 | Sep 30, 2024 | — | — | — | — |
Q3 2024 | Jul 22, 2024 | — | — | — | — |
Q2 2024 | May 29, 2024 | — | — | — | — |
Q1 2024 | Mar 14, 2024 | — | $2.42 | — | — |
Q3 2023 | Sep 30, 2023 | — | $2.32 | — | — |
Q3 2023 | Aug 8, 2023 | — | $-3.37 | — | — |
Q2 2023 | May 31, 2023 | — | $-7.12 | — | — |
Q2 2023 | Apr 28, 2023 | — | $1.60 | — | — |
Q4 2022 | Nov 9, 2022 | — | $-0.37 | — | — |
Q3 2022 | Aug 10, 2022 | — | $-0.33 | — | — |
Q2 2022 | May 11, 2022 | — | $-0.74 | — | — |
Q1 2022 | Mar 24, 2022 | — | $-2.53 | — | — |
Q4 2021 | Nov 10, 2021 | — | $0.74 | — | — |
Q3 2021 | Aug 11, 2021 | — | $-0.99 | — | — |
Q2 2021 | May 12, 2021 | — | $-0.96 | — | — |
Q1 2021 | Mar 25, 2021 | — | $-10.52 | — | — |
Q4 2020 | Oct 26, 2020 | — | $-2.20 | — | — |
Q3 2020 | Aug 13, 2020 | — | $-0.55 | — | — |
Latest News
Frequently Asked Questions about EPGNF
What is EPGNF's current stock price?
What is the analyst price target for EPGNF?
What sector is Epigenomics AG in?
What is EPGNF's market cap?
Does EPGNF pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to EPGNF for comparison